Company intelligence / Profile preview

Lydex Pharmaceuticals

Mount Pleasant, South Carolina, United Statesventureradar.com ↗

Ownership: Private
Development stage: Other

Overview

Lydex Pharmaceuticals developed small molecule HDAC inhibitors for liver ischemia/reperfusion injury and leukemia. Their lead programs were in preclinical development as of early 2025. LP340 showed protective effects against liver injury and fibrosis in animal models, likely via epigenetic upregulation of antioxidant proteins and modulation of inflammatory pathways. No clinical results are available; the company is now defunct.[1][2][3][7]

Therapeutic areas: GastroenterologyOncology
Modalities: Small moleculeHistone deacetylase inhibitor (HDACi)
Industry: Biotech

Partnerships

None reported publicly.

Beyond the preview

Go deeper on Lydex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lydex Pharmaceuticals.

Explore the full profile